{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:57:30Z","timestamp":1780646250607,"version":"3.54.1"},"reference-count":24,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH NIDDK","award":["DK124165"],"award-info":[{"award-number":["DK124165"]}]},{"name":"NIH NCI","award":["CA224319"],"award-info":[{"award-number":["CA224319"]}]},{"name":"NIH NCI","award":["P30 CA196521"],"award-info":[{"award-number":["P30 CA196521"]}]},{"name":"Cancer Research Institute Clinical Strategy Team Grant","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,8,4]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Cisplatin-based chemotherapy has been associated with durable disease control in a small subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this phenomenon has remained elusive. Antitumor immunity may underlie these exceptional responders. In a phase II trial evaluating a phased schedule of gemcitabine and cisplatin followed by gemcitabine and cisplatin with ipilimumab for metastatic urothelial cancer, 4 of 36 patients achieved durable disease-free treatment-free survival (DDFTFS) and remain in remission over 5 years after enrolment on the study. We sought to identify the genomic and immunological mechanisms associated with functional cures of such patients. Whole exome sequencing was performed on pretreatment archival tumor tissue. Neoantigen prediction and ranking were performed using a novel pipeline. For a subset of patients with available biospecimens, selected peptides were tested for neoantigen-specific T cell reactivity in peripheral blood CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells cultured with autologous antigen-presenting cells at baseline, postchemotherapy, and postchemotherapy and ipilimumab timepoints. Multiplex assays of serum protein analytes were also assessed at each time point. Serum proteomic analysis revealed that pretreatment, patients achieving DDFTFS demonstrated an immune activated phenotype with elevations in T<jats:sub>H<\/jats:sub>1 adaptive immunity, costimulatory molecules, and immune checkpoint markers. After combination cisplatin-based chemotherapy and ipilimumab treatment, DDFTFS patients again displayed enrichment for markers of adaptive immunity, as well as T cell cytotoxicity. CD27 was uniquely enriched in DDFTFS patients at all timepoints. Neoantigen reactivity was not detected in any patient at baseline or post two cycles of chemotherapy. Both CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> neoantigen-specific T cell reactivity was detected in two of two DDFTFS patients in comparison to zero of five non-DDFTFS patients after combination cisplatin-based chemotherapy and ipilimumab treatment. Antitumor immunity may underlie functional cures achieved in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy and immune checkpoint blockade. Probing the mechanistic basis for DDFTFS may facilitate the identification of biomarkers, therapeutic components, and optimal treatment sequences necessary to extend this ultimate goal to a larger subset of patients.<\/jats:p>","DOI":"10.1136\/jitc-2023-007613","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:27:33Z","timestamp":1692707253000},"page":"e007613","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01524991","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03682068","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-0346","authenticated-orcid":false,"given":"Jonathan","family":"Anker","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA"},{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[{"name":"Sema4, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Halperin","sequence":"additional","affiliation":[{"name":"Sema4, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Uzilov","sequence":"additional","affiliation":[{"name":"Sema4, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Imai","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Eikawa","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Osaka University School of Medicine Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sebra","sequence":"additional","affiliation":[{"name":"Sema4, Branford, Connecticut, USA"},{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manishkumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-1882","authenticated-orcid":false,"given":"Jingjing","family":"Qi","sequence":"additional","affiliation":[{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA"},{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA"},{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Galsky","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA"},{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"2025100300165433000_11.8.e007613.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"2025100300165433000_11.8.e007613.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"2025100300165433000_11.8.e007613.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.08.032"},{"key":"2025100300165433000_11.8.e007613.4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of Neoadjuvant dose-dense Gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100300165433000_11.8.e007613.5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0623"},{"key":"2025100300165433000_11.8.e007613.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009"},{"key":"2025100300165433000_11.8.e007613.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611618104"},{"key":"2025100300165433000_11.8.e007613.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1298"},{"key":"2025100300165433000_11.8.e007613.9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","article-title":"Phase 2 trial of Gemcitabine, cisplatin, plus Ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes","volume":"73","author":"Galsky","year":"2018","journal-title":"Eur Urol"},{"key":"2025100300165433000_11.8.e007613.10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-9-488","article-title":"Biovenn \u2013 a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics"},{"key":"2025100300165433000_11.8.e007613.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01807","article-title":"Computational pipeline for the PGV-001 Neoantigen vaccine trial","volume":"8","author":"Rubinsteyn","year":"2017","journal-title":"Front Immunol"},{"key":"2025100300165433000_11.8.e007613.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2025100300165433000_11.8.e007613.13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved Dendritic-cell regulatory program limits Antitumour immunity","volume":"582","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"2025100300165433000_11.8.e007613.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"2025100300165433000_11.8.e007613.15","doi-asserted-by":"crossref","first-page":"S682","DOI":"10.1016\/j.annonc.2021.08.054","article-title":"658Mo cisplatin (Cis)-Related Immunomodulation and efficacy with Atezolizumab (Atezo) + Cis- vs carboplatin (Carbo)-Based chemotherapy (Chemo) in metastatic urothelial cancer (mUC)","volume":"32","author":"Galsky","year":"2021","journal-title":"Annals of Oncology"},{"key":"2025100300165433000_11.8.e007613.16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158199","article-title":"Targeting DNA damage response and repair to enhance therapeutic index in cisplatin-based cancer treatment","volume":"22","author":"Kiss","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100300165433000_11.8.e007613.17","first-page":"2509","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100300165433000_11.8.e007613.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1635"},{"key":"2025100300165433000_11.8.e007613.19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS499","article-title":"A phase III, randomized, open-label, multicenter, global study of first-line (1L) Durvalumab in combination with standard of care (Soc) chemotherapy and Durvalumab in combination with Tremelimumab and Soc chemotherapy versus Soc chemotherapy alone in patients with Unresectable locally advanced or metastatic urothelial cancer (UC)","volume":"37","author":"Galsky","year":"2019","journal-title":"JCO"},{"key":"2025100300165433000_11.8.e007613.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715909","article-title":"Targeting the Cd27-Cd70 pathway to improve outcomes in both Checkpoint Immunotherapy and allogeneic hematopoietic cell transplantation","volume":"12","author":"Lutfi","year":"2021","journal-title":"Front Immunol"},{"key":"2025100300165433000_11.8.e007613.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4574"},{"key":"2025100300165433000_11.8.e007613.22","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.4049\/jimmunol.1801022","article-title":"Identification of Neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer","volume":"202","author":"Leko","year":"2019","journal-title":"The Journal of Immunology"},{"key":"2025100300165433000_11.8.e007613.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29342-0","article-title":"Neoantigen-specific Cd8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma","volume":"13","author":"Holm","year":"2022","journal-title":"Nat Commun"},{"key":"2025100300165433000_11.8.e007613.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:17:05Z","timestamp":1759475825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jitc-2023-007613"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007613","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}